Clinical Trials Browser

Enrolling by invitation × INDUSTRY × tislelizumab × Clear all

NCT04164199 2026-03-16

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Phase 3 Enrolling by invitation

Advanced Malignancies